X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The companies will enter into a clinical trial collaboration evaluating XL092 (zanzalintinib), a tyrosine kinase inhibitor, in combination with AB521 in patients with advanced solid tumors including clear cell renal cell carcinoma.
Lead Product(s): Encoberminogene Rezmadenovec,AB521
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arcus Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 04, 2023
Details:
XL092 (Zanzalintinib) is a Vegf/metaxl/mer Inhibitor small molecule drug candidate, which is currently being evaluated in combination with "Pembrolizumab" for the treatment of PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck.
Lead Product(s): Encoberminogene Rezmadenovec,Pembrolizumab
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
XC001 (encoberminogene rezmadenovec) is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow in patients with refractory angina.
Lead Product(s): Encoberminogene Rezmadenovec
Therapeutic Area: Cardiology/Vascular Diseases Product Name: XC001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
Zanzalintinib, which was adopted as the generic name for XL092, is a next-generation tyrosine kinase inhibitor (TKI) in development for multiple advanced tumor types. Zanzalintinib is currently being developed for the treatment of advanced solid tumors.
Lead Product(s): Encoberminogene Rezmadenovec,Nivolumab
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that alters the unfolded protein response (UPR) through selective GRP78 inhibition and induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest.
Lead Product(s): Encoberminogene Rezmadenovec,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
XL092 is a next-generation oral TKI that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER.
Lead Product(s): Encoberminogene Rezmadenovec,Nivolumab
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 04, 2022
Details:
XL092 demonstrated preliminary clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors and dose levels, with a manageable safety profile.
Lead Product(s): Encoberminogene Rezmadenovec,Atezolizumab
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition.
Lead Product(s): Encoberminogene Rezmadenovec,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: BOLD-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
STELLAR-303 is a global, multicenter, randomized phase 3 open-label study that will enroll approximately 600 patients with documented RAS status. Patients will be randomized 1:1 to receive either XL092 in combination with atezolizumab or regorafenib.
Lead Product(s): Encoberminogene Rezmadenovec,Atezolizumab
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
The objective of the study is to evaluate the safety, tolerability and efficacy of XL092, Exelixis’ novel next-generation tyrosine kinase inhibitor (TKI), in combination with: nivolumab (OPDIVO®); nivolumab and ipilimumab (YERVOY®); and nivolumab and bempegaldesleukin.
Lead Product(s): Encoberminogene Rezmadenovec,Nivolumab
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 14, 2021
Details:
Avelumab is being co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer. Exelixis is sponsoring the STELLAR-001 clinical trial, and Merck KGaA, Darmstadt, Germany and Pfizer will provide avelumab for use in the trial.
Lead Product(s): Encoberminogene Rezmadenovec,Avelumab
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 18, 2021
Details:
XL092 is an investigational, next-generation oral TKI, currently in phase 1 trial evaluating its safety, tolerability, pharmacokinetics & preliminary anti-tumor activity alone and in combination with atezolizumab (TECENTRIQ®) in patients with advanced solid tumors.
Lead Product(s): Encoberminogene Rezmadenovec,Atezolizumab
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
The data to be presented at the ENA Symposium suggest XL092 has a desirable therapeutic profile that pairs the potential for significant anti-tumor activity with a much shorter clinical half-life than cabozantinib.
Lead Product(s): Encoberminogene Rezmadenovec,Atezolizumab
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
